PCIF1 and urinary bladder cancer: In gastric cancer, colorectal cancer and bladder cancer, PCIF1 KO can reduce tumor migration, invasion and other malignant behaviors, reduce subcutaneous tumorigenesis, and even reduce lung metastasis, indicating that PCIF1 may be a target for tumor treatment in the future [29, 32, 44].